

## SEMI-ANNUAL CHANGES TO THE NASDAQ BIOTECHNOLOGY INDEX

**New York, NY**—The Nasdaq Stock Market, Inc. ("NASDAQ"; OTCBB: NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index<sup>®</sup> (NASDAQ: NBI), which will become effective with the market open on Monday, November 24, 2003.

The re-ranking will result in 55 securities being added to the Index. As announced on November 11, 2003, NASDAQ will reclassify its companies according to the FTSE Global Classification System<sup>™</sup>. The first step in this process is basing the NASDAQ Biotechnology Index on FTSE's biotechnology and pharmaceutical sub-sectors. The securities that meet the classification criteria then must meet other Index eligibility criteria including listing on the NASDAQ National Market and meeting minimum requirements for market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit [www.NASDAQ.com](http://www.NASDAQ.com).

The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology Index<sup>SM</sup> Fund (Amex: IBB), which seeks investment results that generally correspond to the price and yield performance of the NASDAQ Biotechnology Index before fees and expenses. In addition, options based on the NASDAQ Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on various exchanges.

NASDAQ is the world's largest electronic stock market. With approximately 3,400 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to category-defining companies that are leaders across all areas of business including technology, retail, communications, financial services, media and biotechnology.

For more information about NASDAQ, visit the NASDAQ Web site at [www.NASDAQ.com](http://www.NASDAQ.com) or the NASDAQ Newsroom<sup>SM</sup> at [www.NASDAQnews.com](http://www.NASDAQnews.com)

---

The FTSE Global Classification System is compiled by FTSE International Limited.  
©FTSE International Limited 2003.

FTSE<sup>™</sup> is a trademark of the London Stock Exchange Plc and The Financial Times Limited and is used by FTSE International Limited under license.

iShares are distributed by SEI Investments Distribution Co. Barclays Global Fund Advisors serves as an advisor to iShares and is a subsidiary of Barclays Global Investors, N.A., neither of which is affiliated with SEI. For a prospectus, call 1-800-iSHARES (1-800-474-2737).

**iShares are not FDIC Insured.  
Have No Bank Guarantee.  
May Lose Value.**

## Company Briefs

aaiPharma Inc. (NASDAQ:AII) is a specialty pharmaceutical and product development company with drug development capabilities in the United States, Europe, and Asia. The Company partners with pharmaceutical companies on both a fee-for-service and royalty payment basis. aaiPharma is also focusing on the launching of its own brand of products in the areas of immunosuppression and pain management.

Able Laboratories, Inc. (NASDAQ:ABRX) develops and manufactures generic pharmaceuticals. The Company focuses on developing products that offer market opportunities within selected niche markets of the generic drug industry. Able currently sells several products and has several products in various stages of Federal Drug Administration approval.

Adolor Corporation (NASDAQ:ADLR) is a therapeutic-based biopharmaceutical company. The Company discovers, develops, and commercializes pharmaceutical products for the treatment of pain and the side effects that are caused by current narcotic pain treatments. Adolor's small molecule product candidates are in clinical trials.

AtheroGenics, Inc. (NASDAQ:AGIX) develops and commercializes small molecule therapeutics for the treatment of chronic inflammatory diseases such as atherosclerosis, asthma, and arthritis. These treatments are designed to suppress inflammation without undermining the body's ability to protect itself against infection.

Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI) develops drug-coated medical devices and drug-loaded surgical implants. The Company enhances the performance of medical devices and surgical implants through the use of pharmacotherapeutics. Angiotech is the original developer of the paclitaxel-eluting coronary stent, a drug-loaded medical device.

American Pharmaceutical Partners, Inc. (NASDAQ:APPX) develops, manufactures, and markets injectable pharmaceutical products. The Company's primary focus is on the oncology, anti-infective, and critical care markets.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.

Axcan Pharma Inc. (NASDAQ:AXCA) is a pharmaceutical company. The Company researches, develops, and distributes pharmaceutical products, mainly in the field of gastroenterology. Axcan's products treat inflammatory bowel diseases, irritable bowel syndrome, cholestatic diseases of the liver, and infections as encountered in cystic fibrosis patients.

Biopure Corporation (NASDAQ:BPUR) develops, manufactures, and markets Oxygen Therapeutic solutions. The Company's products are pharmaceuticals which are intravenously administered to deliver oxygen to the body's tissues. Biopure's products include Oxyglobin, a treatment for anemia in dogs, and Hemopure, an investigational Oxygen Therapeutic solution for human use.

Biosite Incorporated (NASDAQ:BSTE) is a research-based company that discovers and develops novel protein-based diagnostic tests. The Company's products improve a physician's ability to diagnose debilitating and life-threatening diseases. Biosite's Triage brand rapid diagnostic tests are used in United States hospitals and international markets.

Ciphergen Biosystems, Inc. (NASDAQ:CIPH) develops, manufactures, and markets a proprietary ProteinChip System that enables protein discovery, characterization, and assay development. The system provides better understanding of biological functions at the protein level.

Connetics Corporation (NASDAQ:CNCT) is a pharmaceutical company focused on late-stage product development and commercialization for dermatology and other specialty medical markets. The Company currently markets Luxiq foam for the treatment of scalp dermatoses, Ridaura for the treatment of rheumatoid arthritis, and Actimmune for the treatment of infections resulting from chronic granulomatous disease.

deCODE genetics, Inc. (NASDAQ:DCGN) is developing gene and drug target discovery, database, and information technology products and services for the healthcare industry using human genetics. The Company develops and applies information technology to discover new knowledge about health and disease through data mining.

Digene Corporation (NASDAQ:DIGE) develops, manufactures, and markets DNA and RNA tests for the detection, screening, and monitoring of human diseases. The Company's products are designed to help improve clinical outcomes and reduce the overall cost of disease management. Digene's lead product aids physicians in identifying women who are at a high risk for cervical cancer and disease.

Dendreon Corporation (NASDAQ:DNDN) discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company combines knowledge in immunology and antigen engineering with proprietary cell separation technologies to develop therapeutic vaccines that induce cell-mediated immunity, the body's key defense against cancer.

Eon Labs, Inc. (NASDAQ:ELAB) develops, licenses, manufactures, sells, and distributes a range of prescription pharmaceutical products. The Company utilizes an integrated approach to select and develop generic pharmaceutical products in both niche and high volume markets. Eon focuses on drugs in a broad range of solid oral dosage forms, utilizing both immediate and sustained release delivery.

Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) discovers, develops, and commercializes novel drugs, focusing on small molecule drug development and vascular biology. The Company's initial product, Argatroban, is being marketed for

heparin-induced thrombocytopenia. Encysive is also developing the endothelin antagonist, sistaxsentan, for pulmonary arterial hypertension.

Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) is a specialty pharmaceutical company with products that provide pain management. The Company researches, develops, produces, and markets both branded and generic pharmaceuticals. Endo's products include Percocet, Percodan, and Lidoderm.

EPIX Medical, Inc. (NASDAQ:EPIX) develops targeted contrast agents to improve the capability of magnetic resonance imaging (MRI) as a diagnostic tool for a variety of diseases. The Company's principal product under development, AngioMARK, is an investigational new drug designed to enhance MRI.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) discovers and develops pharmaceutical products for the treatment of cardiovascular disease. The Company is testing therapies that may enhance the naturally occurring processes in the body for the removal of excess cholesterol.

EXACT Sciences Corporation (NASDAQ:EXAS) has developed technologies that will enable genomics based detection of colorectal cancer and other types of common cancer. The Company's technologies isolate human DNA shed into stool and then detect the minute amount of abnormal DNA associated with colorectal cancer.

First Horizon Pharmaceutical Corporation (NASDAQ:FHRX) is a pharmaceutical company focused on the development and marketing of prescription pharmaceuticals for the treatment of chronic diseases. The Company currently markets prescription products to high prescribing physicians throughout the United States.

Flamel Technologies S.A. (NASDAQ:FLML) develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. The Company's programs include "Micropump" and "Medusa" in drug delivery, and "ColCys" in biomaterial-based medical devices. Flamel builds on its technology platforms to develop other products, such as new materials for ophthalmic lens products.

Gen-Probe Incorporated (NASDAQ:GPRO) develops, manufactures, and commercializes diagnostic products based on its genetic probe technologies.

Harvard Bioscience, Inc. (NASDAQ:HBIO) develops, manufactures, and markets tools used in drug discovery research and pharmaceutical and biotechnology companies, universities, and government laboratories. The Company's tools include proteomics products that allow researchers to purify and analyze proteins and ADMET screening products that test drug candidates.

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) discovers, develops, and commercializes products for the treatment of a number of targeted disease states caused by viral, bacterial, parasitic, or fungal infections. The Company's technology platforms are based on cellular energy regulation, an immune system modulation technology, and on biochemical synthesis regulators.

Indevus Pharmaceuticals, Inc. (NASDAQ:IDEV) develops and commercializes products and product candidates, including multiple compounds in late-stage clinical

development. The Company is developing compounds for the treatment of panic disorders, overactive bladder, cirrhosis of the liver, strokes, and inflammatory bowel disease, as well as a compound for the prevention of infection by certain diseases.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) provides diagnostic, detection, and information systems for veterinary, food, and water testing applications. The Company also operates an international network of veterinary reference laboratories. IDEXX offers its products to customers worldwide.

Introgen Therapeutics, Inc. (NASDAQ:INGN) develops gene therapy products for the treatment of cancer. The Company's lead product candidate combines the p53 gene, a tumor suppressor gene, with a gene delivery system that it has developed and tested. Introgen is developing cancer therapies that are based on restoring normal cellular function through gene therapy.

Impax Laboratories, Inc. (NASDAQ:IPXL) develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The Company specializes in the development of niche and controlled release generics, as well as the development of branded products.

Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) discovers and develops pharmaceutical products to treat diseases that result from deficiencies in the body's natural mechanisms of mucosal hydration. The Company's lead products target respiratory and ophthalmic diseases with inadequate current treatments, including a respiratory for chronic bronchitis and an ophthalmic for dry eye disease.

Kos Pharmaceuticals, Inc. (NASDAQ:KOSP) is a fully integrated specialty pharmaceutical company that develops and commercializes proprietary prescription pharmaceutical products. The Company's products are for use in the treatment of chronic cardiovascular and respiratory diseases. Kos has drug-delivery capabilities in both solid-dose and aerosolized formulation technologies.

Lexicon Genetics Incorporated (NASDAQ:LEXG) discovers breakthrough treatments for human disease. The Company is using gene knockout technology to systematically discover the physiological functions and pharmaceutical utility of genes. Lexicon's gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, and cancer.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) researches and develops specialized therapeutics for the treatment of diseases caused by antibodies. The Company is developing products to treat autoimmune conditions such as lupus and antibody-mediated stroke.

Martek Biosciences Corporation (NASDAQ:MATK) develops, manufactures, and sells products derived from microalgae. The Company's products include nutritional oils for infant formula, nutritional supplements and food ingredients, reagents to visualize molecular interactions for drug discovery and development, and fluorescent markers for diagnostics, miniaturized screening, and gene detection.

Vicuron Pharmaceuticals Inc. (NASDAQ:MICU) is an international biopharmaceutical company that discovers, develops, manufactures, and commercializes vital medicine

for seriously ill patients. The Company's lead product candidates include a novel antifungal agent and a novel intravenous antibiotic for the treatment of serious Gram-positive infections.

Nabi Biopharmaceuticals (NASDAQ:NABI) is a vertically integrated biopharmaceutical company focused on drugs that prevent and treat infectious and autoimmune diseases. The Company currently provides biopharmaceuticals, including Nabi-HB for the prevention of hepatitis B infections, and WinRho SDF for the treatment of HIV-related immune thrombocytopenia. Nabi also has a clinical trials program.

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) develops transdermal and transmucosal drug delivery systems and technologies. The Company's products include Vivelle and Vivelle Dot estrogen transdermal delivery systems, DentiPatch transmucosal patch, and CombiPatch and Estalis estrogen/progestin transdermal delivery systems. Noven also has other products in development.

Neurochem Inc. (NASDAQ:NRMX) is a specialty pharmaceutical company that offers a new class of drug candidates to prevent and stop the progression of diseases for which no cure exists. The Company is focusing on unmet medical needs of disorders of the central nervous system and amyloid-related diseases. Neurochem's product candidates include Fibrillex, Alzhemed, and Cerebril.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) discovers and develops novel therapeutics based upon the genetics of human disease, with an emphasis on cancer. The Company focuses on defining the function of certain mutated genes that are known to cause cancer, and on developing therapies to reverse the effects of the mutation or to kill the cancer cell.

Priority Healthcare Corporation (NASDAQ:PHCC) distributes specialty pharmaceuticals and related medical supplies to the alternate healthcare market. The Company also provides patient-specific, self-injectable biopharmaceuticals and disease treatment programs to individuals with chronic diseases. Priority distributes its products across the United States.

POZEN Inc. (NASDAQ:POZN) develops pharmaceutical products in select therapeutic areas. The Company's MT 100 product is an oral first-line therapy for the treatment of migraine. POZEN also develops drugs for diseases of the gastrointestinal and respiratory tracts, oncology, and infectious diseases.

Penwest Pharmaceuticals Co. (NASDAQ:PPCO) researches, develops, and commercializes novel drug delivery technologies. The Company's proprietary TIMERx controlled release drug delivery technology is applicable to a broad range of orally administered drugs. Penwest's product portfolio ranges from excipients that are sold in bulk, to more advanced and patented excipients that are licensed to customers.

Perrigo Company (NASDAQ:PRGO) manufactures store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. The Company's customers include major national and regional retail drug, supermarket, and mass merchandise chains such as Albertson's, CVS, and Target, and major wholesalers such as Super Valu and McKesson.

PAREXEL International Corporation (NASDAQ:PRXL) is a contract research and product launch organization. The Company provides outsourcing services to the worldwide pharmaceutical, biotechnology and medical device industries. PAREXEL has operations in various countries around the world.

Pain Therapeutics, Inc. (NASDAQ:PTIE) is developing a new generation of opioid painkillers. The Company uses its proprietary technology to reformulate opioid drugs, such as morphine, into new painkillers. Pain Therapeutics currently has several products in Phase II clinical trials.

Sepracor Inc. (NASDAQ:SEPR) is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development, and commercialization of innovative pharmaceutical products that are directed to unmet medical needs. The company's drug development programs are focused on the treatment of respiratory, urology, and central nervous system disorders.

SFBC International, Inc. (NASDAQ:SFCC) is a contract research organization that conducts clinical research and provides drug development services for clients in the pharmaceutical and biotechnology industries.

Shire Pharmaceuticals Group plc (NASDAQ:SHPGY) specializes in the marketing, licensing and development of prescription medicines. The Group focuses its operations towards four therapeutic areas: central nervous system disorders, oncology/hematology, antivirals and biologics. Shire sells and markets its products in the United States, Canada, Ireland, France, Germany, Italy, Spain, and the United Kingdom.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. The Company's COLAZAL product is an anti-inflammatory drug used for the treatment of mildly to moderately active ulcerative colitis.

SuperGen, Inc. (NASDAQ:SUPG) is a pharmaceutical company that acquires, develops, and markets products for the treatment of life-threatening diseases, particularly cancer. The Company is marketing Nipent in the United States for the treatment of hairy cell leukemia. SuperGen is also conducting late stage clinical trials on a drug that has the potential to treat a variety of solid tumors.

Savient Pharmaceuticals Inc. (NASDAQ:SVNT) develops, manufactures, and markets human health care products for niche and wider markets. The Company markets Oxandrin and Delatestryl in the United States. Savient's United Kingdom subsidiary develops oral liquid formulations of prescription products, and its Israeli subsidiary manufactures Bio-Tropin, BioLon, Bio-Hep-B, and Arthrase.

Taro Pharmaceutical Industries Ltd. (NASDAQ:TARO) is a multinational, science-based pharmaceutical company that discovers, develops, manufactures, and markets healthcare products. The Company's products include prescription and over-the-counter drugs.

Techne Corporation (NASDAQ:TECH), through Research and Diagnostic Systems, Inc., manufactures biological products. The Company also, through R&D Systems Europe, Ltd., distributes biotechnology products.

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system.

Source: Bloomberg